ArticleBrain and behavior2025
Exploring Contraindicated Medications and Corresponding Targeted Genes for Migraine Through Integrated Genetic Approaches.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring Contraindicated Medications and Corresponding Targeted Genes for Migraine Through Integrated Genetic Approaches.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify contraindicated medications and corresponding target genes for migraine and its subtypes.
methodUtilizing the Genome-Wide Association Studies (GWAS) for 14 medication-use categories from UK Biobank and GWAS for migraine and its subtypes from FinnGen, our study revealed potential contraindicated drugs for the chronic paroxysmal neurological disorder based on Mendelian randomization (MR). Then we applied the Transcriptome-wide association study (TWAS) within the framework of Omnibus Transcriptome Test using Expression Reference Summary data (OTTERS) and cross-referenced three drug databases to determine the targeted genes of the identified contraindicated medications. Moreover, Summary-data-based Mendelian Randomization (SMR) and INtegration of TWAS And ColocalizaTion (INTACT) were used as sensitivity analyses to further validate the associations and strengthen causal inference. We also performed brain-tissue TWAS across 13 regions to confirm the tissue-specific associations of the hub genes with migraine and its subtypes.
resultsMR analysis revealed that the diuretics and agents that act on the renin-angiotensin system were discovered to be associated with an increased risk of migraine and migraine with aura. By intersecting the results from TWAS and drug databases, 37 and 22 target genes of contraindicated medications were identified for migraine and migraine with aura, respectively. SMR and INTACT confirmed the validity of BLM, C12orf76, GPATCH4, PAM, SERPINC1 for migraine, and ALMS1, GPATCH4, NCF2, SLC12A1, ZKSCAN8P1 for migraine with aura. At the brain-tissue level, we further validated hub gene associations: in migraine, SERPINC1, ZKSCAN8P1, C12orf76, and PAM were significant across brain regions; in migraine with aura, SERPINC1, ALMS1, ZKSCAN8P1, PAM, and NCF2 were significant.
conclusionWe identified the diuretics and agents that act on the renin-angiotensin system as the contraindicated medications for migraine and migraine with aura, and BLM, C12orf76, GPATCH4, PAM, SERPINC were found as the targeted genes of contraindicated drugs for migraine and ALMS1, GPATCH4, NCF2, SLC12A1, ZKSCAN8P1 for migraine with aura, providing new clues for the preventive strategies for migraine and its subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.